Nancy Wysenski has bought ALKS on 2 days since Feb 2019

Nancy J. Wysenski is a biopharmaceutical executive and corporate director who has served on the board of Alkermes plc for a decade, including as Lead Independent Director during the company’s board refreshment process.( As a corporate insider at Alkermes, she has reported transactions in the company’s securities and is identified in SEC filings as a director of Alkermes plc and trustee and beneficiary of The Nancy J. Wysenski Revocable Trust.( She retired from Alkermes’ board in December 2023 after ten years of service.(

Wysenski has more than 30–35 years of healthcare and biopharmaceutical leadership experience, including senior commercial and operational roles at Vertex Pharmaceuticals (Executive Vice President and Chief Commercial Officer, leading the launches of Incivek and Kalydeco) and Endo Pharmaceuticals (Chief Operating Officer responsible for sales, marketing, commercial operations, supply chain, HR, and business development).( She founded EMD Pharmaceuticals, Inc., the North American subsidiary of Merck KGaA, and served as its President and CEO from 2001 to 2006 after earlier leadership roles as Vice President of Commercial.( Her career began in nursing at the Veterans Administration Medical Center in Cleveland before progressing through multiple sales and field leadership roles at Merck Human Health and Astra Merck, including Vice President of Field Sales.( Wysenski has held board positions at Cytokinetics, Provention Bio, Tetraphase, Dova, Reata, and Inovio Pharmaceuticals and is a founder of the Research Triangle Park chapter of the Healthcare Businesswomen’s Association.( She holds a B.S.N. in Nursing from Kent State University and an MBA from Baldwin-Wallace College.(

Written by Perplexity from public sources.